Healthcare

Universal Health Services runs acute care hospitals and a leading behavioral health network. Revenue, margins, and cash flow have strengthened, while the stock trades at a notably lower earnings multiple than much of healthcare, making its operating recovery worth a closer look.

10x Genomics builds advanced tools for single-cell and spatial biology, supplying labs with instruments and recurring consumables. The appeal rests on strong technology, a growing installed base, and improving cash generation as these research markets evolve.

Twist Bioscience makes synthetic DNA at scale and is expanding into antibody discovery and sequencing tools. Revenue growth remains strong and losses have narrowed sharply, making the company a more credible platform business than it was a few years ago.

Tempus AI combines precision diagnostics, clinical software, and large-scale medical data to serve physicians and drug developers. Revenue growth has been strong and the platform is expanding, making its path to scale and margin improvement especially important to watch.

Bio-Techne supplies research and diagnostic tools used across biology, drug development, and clinical testing. Strong profitability, low debt, and exposure to spatial biology and cell therapy make it a compelling company to examine, especially as margins recover.